GSA Capital Partners LLP Sells 835 Shares of NuVasive, Inc. (NUVA)
GSA Capital Partners LLP lowered its stake in NuVasive, Inc. (NASDAQ:NUVA) by 19.7% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,401 shares of the medical device company’s stock after selling 835 shares during the quarter. GSA Capital Partners LLP’s holdings in NuVasive were worth $262,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in NuVasive by 4.9% in the 1st quarter. Vanguard Group Inc. now owns 4,110,457 shares of the medical device company’s stock valued at $306,969,000 after buying an additional 191,166 shares in the last quarter. State Street Corp lifted its stake in NuVasive by 2.5% in the 1st quarter. State Street Corp now owns 1,641,997 shares of the medical device company’s stock valued at $122,617,000 after buying an additional 40,416 shares in the last quarter. Victory Capital Management Inc. lifted its stake in NuVasive by 14.4% in the 2nd quarter. Victory Capital Management Inc. now owns 818,001 shares of the medical device company’s stock valued at $62,921,000 after buying an additional 102,680 shares in the last quarter. TIAA CREF Investment Management LLC lifted its stake in NuVasive by 118.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 546,740 shares of the medical device company’s stock valued at $42,055,000 after buying an additional 296,715 shares in the last quarter. Finally, Neuberger Berman Group LLC lifted its stake in NuVasive by 8.9% in the 2nd quarter. Neuberger Berman Group LLC now owns 439,121 shares of the medical device company’s stock valued at $33,777,000 after buying an additional 35,866 shares in the last quarter.
Shares of NuVasive, Inc. (NASDAQ:NUVA) opened at 54.57 on Friday. The stock’s 50 day moving average price is $56.23 and its 200-day moving average price is $68.79. The firm has a market capitalization of $2.77 billion, a P/E ratio of 85.94 and a beta of 1.03. NuVasive, Inc. has a 12-month low of $49.25 and a 12-month high of $81.68.
NuVasive (NASDAQ:NUVA) last posted its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The firm had revenue of $260.60 million during the quarter, compared to analyst estimates of $261.95 million. During the same quarter last year, the business posted $0.40 EPS. The company’s revenue was up 10.3% on a year-over-year basis. On average, equities analysts expect that NuVasive, Inc. will post $1.99 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “GSA Capital Partners LLP Sells 835 Shares of NuVasive, Inc. (NUVA)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/gsa-capital-partners-llp-sells-835-shares-of-nuvasive-inc-nuva/1642711.html.
A number of equities research analysts recently issued reports on NUVA shares. Needham & Company LLC lowered NuVasive from a “hold” rating to an “underperform” rating in a research note on Monday, August 28th. BTIG Research started coverage on NuVasive in a research note on Thursday, September 7th. They issued a “buy” rating and a $82.00 target price on the stock. Cowen and Company reaffirmed an “outperform” rating and issued a $83.00 target price on shares of NuVasive in a research note on Monday, September 18th. BidaskClub upgraded NuVasive from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $79.00 price target on shares of NuVasive in a report on Tuesday, October 3rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have given a buy rating to the company’s stock. NuVasive has an average rating of “Buy” and an average price target of $74.62.
In other NuVasive news, Director Lesley H. Howe sold 3,970 shares of NuVasive stock in a transaction on Friday, August 18th. The shares were sold at an average price of $64.64, for a total transaction of $256,620.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Peter Michael Leddy bought 7,850 shares of the firm’s stock in a transaction on Tuesday, August 1st. The shares were bought at an average cost of $63.88 per share, with a total value of $501,458.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 14,850 shares of company stock valued at $955,598 in the last three months. Company insiders own 1.20% of the company’s stock.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.